Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 [WEBINAR] Scalable Oligonucleotide Manufacture With Stirred-Bed Technology | Contract Pharma

What are you searching for?

Sign in
News Releases

[WEBINAR] Scalable Oligonucleotide Manufacture With Stirred-Bed Technology

Wednesday, May 24th, 2023 - 11:00 AM ET / 17:00 AM Europe/Zurich

Released By Bachem

Based on decades of experience in applying stirred-bed reactors for making peptides, we investigated whether these could be used for the manufacturing of oligonucleotides as well. Join our webinar on scalable oligonucleotide manufacturing with stirred-bed technology (SBT) to learn how we can reach commercial oligonucleotides API production in metric ton range with unbeaten process mass intensity. You will get insights into case studies, our SBT capacities for R&D to large scale production projects, and typical CMC activities for scale-up. Finally, we will share the distinct advantages stirred-bed solid-phase oligonucleotide synthesis (SPOS) has over classical fixed-bed SPOS.

Speakers:

Daniel Samson, PH.D. – Vice President, Head Oligonucleotides

Daniel brings 15 years of industry experience to the team, with an emphasis on TIDES process R&D, manufacturing and CMC development. He leads Bachem’s oligonucleotide unit including innovation projects, R&D and manufacturing activities. Daniel holds a PhD in organic chemistry from the University of Konstanz, and an MBA from the International Institute for Management Development (IMD), Lausanne. In previous stages of his career he was a lab head for process optimization, technology transfer, Quality by Design, and scale-up of synthetic peptide manufacturing procedures. From 2012, Daniel was a Vice President API Manufacturing and had full responsibility for all large-scale solid phase peptide and oligonucleotide syntheses, downstream operations, and CMC activities within Bachem AG.

Chris Mcgee, PH.D. – Vice President, Head Global Business Development

Chris leads the Global Business Development department at Bachem. Previously, he was Senior Director of Business Development (BD) for Bachem Americas. As Senior Director of BD, he was at the forefront of communications related to the development and manufacturing of new peptide and oligonucleotide-based chemical entities with his team of peptide experts in the field. Chris has nearly a decade of experience at Bachem and previously earned a Ph.D. in organic chemistry from the University of California, Irvine.

Click here to register now >>>

Request more information from Bachem

Request more information from Bachem

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics